Rojas A, González I, Morales MA. Natural products and cancer: The urgent need to bridge the gap between preclinical and clinical research.
World J Gastrointest Oncol 2025;
17:100484. [DOI:
10.4251/wjgo.v17.i4.100484]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2024] [Revised: 01/20/2025] [Accepted: 01/27/2025] [Indexed: 03/25/2025] Open
Abstract
Any new report on the anticancer properties of natural products always awakens new satisfaction and hope about the role of the international scientific community in its continuous contributions to human health, particularly when those reports contribute to both the understanding and therapeutics of cancer. For many decades, natural products have been pivotal in drug discovery programs because they offer a diverse array of anticancer therapeutic possibilities. Recently, two manuscripts published in the World Journal of Gastrointestinal Oncology added new data to the already extensive body of anticancer preclinical evidence for resveratrol and senegenin, two compounds widely present in herbal preparations used in traditional Chinese medicine. The first one, with comprehensive and recognized anticancer properties, and the second one, shows a compelling body of evidence supporting its neuroprotective effects, but with emerging anticancer activities. Natural products have become key elements in the expanding and dynamic field of anticancer drug discovery. However, urgent and collective efforts are still needed to bridge the gap between preclinical and clinical research and thus bring new anticancer therapeutic breakthroughs.
Collapse